Top news
Pfizer, BioNTech ask FDA for full approval of Covid-19 vaccine
By Erika Edwards & Akshay Syal
Why we shouldn't panic about the millions who missed their second vaccine dose—yet
By Maya Wei-Haas
Pfizer CEO Says Lower-Income Countries Didn't Order Vaccines
By Riley Griffin
All coverage
Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues
By Kevin Breuninger
BioNTech nearing request for approval of longer-lasting version of COVID vaccine
By Louise Heavens, Ludwig Burger & Alistair Smout
AstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say
By Siladitya Ray
BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says
By Noah Higgins-Dunn
Pfizer-BioNTech Vaccine is Highly Effective Against Variants, Studies Find (Published 2021)
By Emily Anthes
How the Moderna, AstraZeneca, Pfizer and other Covid vaccines compare
By Annelies Gartner, Anne Gulland & Jennifer Rigby
Pfizer to seek authorization for Covid-19 vaccine for children ages 2 to 11 in September
By Naomi Thomas
Pfizer Seeks Full FDA Approval For COVID-19 Vaccine
By Emma Bowman
FDA preparing to authorize Pfizer Covid vaccine for 12- to 15-year-olds as early as next week
By Lauren Egan & Laura Strickler
Canada allows Pfizer COVID-19 vaccine for children aged 12-15
By David Ljunggren
Pfizer sees robust COVID-19 vaccine demand for years, $26 bln in 2021 sales
By Michael Erman & Manas Mishra
Pfizer plans to file for full FDA approval of Covid vaccine at the end of this month
By Berkeley Lovelace & Berkeley Lovelace Jr.
Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine
By Berkeley Lovelace, Berkeley Lovelace Jr. & Dawn Kopecki
Covid-19: F.D.A. to Authorize Pfizer Vaccine for Adolescents by Early Next Week (Published 2021)
By Apoorva Mandavilli, Kate Taylor & Will Wright
Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine (Published 2021)
By Rebecca Robbins & Peter S. Goodman